Terms: = Colorectal cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Treatment
691 results:
1. The use of peripheral CD3
Zhang S; Li L; Liu C; Pu M; Ma Y; Zhang T; Chai J; Li H; Yang J; Chen M; Kong L; Xia T
J Cancer Res Clin Oncol; 2024 Jul; 150(7):365. PubMed ID: 39052085
[TBL] [Abstract] [Full Text] [Related]
2. Pexidartinib and Immune Checkpoint Inhibitors Combine to Activate Tumor Immunity in a Murine colorectal cancer Model by Depleting M2 Macrophages Differentiated by cancer-Associated Fibroblasts.
Shimizu D; Yuge R; Kitadai Y; Ariyoshi M; Miyamoto R; Hiyama Y; Takigawa H; Urabe Y; Oka S
Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000110
[TBL] [Abstract] [Full Text] [Related]
3. Type I Interferon Activates pd-1 Expression through Activation of the STAT1-IRF2 Pathway in Myeloid Cells.
Liang L; Yang Y; Deng K; Wu Y; Li Y; Bai L; Wang Y; Lu C
Cells; 2024 Jul; 13(13):. PubMed ID: 38995014
[TBL] [Abstract] [Full Text] [Related]
4. Targeting CSF1R in myeloid-derived suppressor cells: insights into its immunomodulatory functions in colorectal cancer and therapeutic implications.
Tong X; Qiao S; Dong Z; Zhao X; Du X; Niu W
J Nanobiotechnology; 2024 Jul; 22(1):409. PubMed ID: 38992688
[TBL] [Abstract] [Full Text] [Related]
5. Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer.
Chen Y; Wang D; Li Y; Qi L; Si W; Bo Y; Chen X; Ye Z; Fan H; Liu B; Liu C; Zhang L; Zhang X; Li Z; Zhu L; Wu A; Zhang Z
Cancer Cell; 2024 Jul; 42(7):1268-1285.e7. PubMed ID: 38981439
[TBL] [Abstract] [Full Text] [Related]
6. Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers.
Wang Z; Cheng S; Yao Y; Liu S; Liu Z; Liu N; Jin Y; Zhang Y; Yin F; Han G; Zhang J; Wang Q; Yan D; Wang L; Lu H; Deng T; Ji Z; Gao H; Fang W; Zhang H; Chen Z; Zou J; Tang Y; Xu C; Li J; Qu H; Bao L; Cao B; Wang X; Xu T; Sun Y; Shen L; Peng Z; Li J
Cancer Immunol Immunother; 2024 Jul; 73(9):182. PubMed ID: 38967817
[TBL] [Abstract] [Full Text] [Related]
7. cancer Cell Small Molecule Secretome Induces the Immune Checkpoint NKG2A and Dysfunction of Human CD8+ T Cells.
Rodriguez-Garcia GJ; Graves DK; Mirza MB; Idrees K; Kim YJ; Korrer MJ; Rathmell JC
Immunohorizons; 2024 Jun; 8(6):464-477. PubMed ID: 38922288
[TBL] [Abstract] [Full Text] [Related]
8. Fasting-mimicking diet remodels gut microbiota and suppresses colorectal cancer progression.
Luo M; Wang Q; Sun Y; Jiang Y; Wang Q; Gu Y; Hu Z; Chen Q; Xu J; Chen S; Hou T; Feng L
NPJ Biofilms Microbiomes; 2024 Jun; 10(1):53. PubMed ID: 38918380
[TBL] [Abstract] [Full Text] [Related]
9. Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors.
Berland L; Gabr Z; Chang M; Ilié M; Hofman V; Rignol G; Ghiringhelli F; Mograbi B; Rashidian M; Hofman P
Front Immunol; 2024; 15():1384121. PubMed ID: 38903504
[TBL] [Abstract] [Full Text] [Related]
10. pd-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer.
Pei F; He W; Duan Y; Yao Q; Zhao Y; Fan X; Liu S; Chen H; He F; Liu T; Chen J; Zheng Y; Li H; Guo X; Shi L; Ling L; Chen Y; He J; Liu M; Huang M; Bai Y; Wang J; Huang M; Huang J
Cancer Med; 2024 Jun; 13(12):e7224. PubMed ID: 38888366
[TBL] [Abstract] [Full Text] [Related]
11. Rapamycin circumvents anti pd-1 therapy resistance in colorectal cancer by reducing PD-L1 expression and optimizing the tumor microenvironment.
Jia M; Yuan Z; Yu H; Feng S; Tan X; Long Z; Duan Y; Zhu W; Yan P
Biomed Pharmacother; 2024 Jul; 176():116883. PubMed ID: 38876047
[TBL] [Abstract] [Full Text] [Related]
12. Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
Yu JH; Xiao BY; Li DD; Jiang W; Ding Y; Wu XJ; Zhang RX; Lin JZ; Wang W; Han K; Kong LH; Zhang XK; Chen BY; Mei WJ; Pan ZZ; Tang JH; Zhang XS; Ding PR
Lancet Oncol; 2024 Jul; 25(7):843-852. PubMed ID: 38852601
[TBL] [Abstract] [Full Text] [Related]
13. The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review.
Yang L; Cui X; Wu F; Chi Z; Xiao L; Wang X; Liang Z; Li X; Yu Q; Lin X; Gao C
Front Immunol; 2024; 15():1392499. PubMed ID: 38846948
[TBL] [Abstract] [Full Text] [Related]
14. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
Tsukada Y; Bando H; Inamori K; Wakabayashi M; Togashi Y; Koyama S; Kotani D; Yuki S; Komatsu Y; Homma S; Taketomi A; Uemura M; Kato T; Fukui M; Nakamura N; Kojima M; Kawachi H; Kirsch R; Yoshida T; Sato A; Nishikawa H; Ito M; Yoshino T
Br J Cancer; 2024 Jul; 131(2):283-289. PubMed ID: 38834744
[TBL] [Abstract] [Full Text] [Related]
15. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study.
Overman MJ; Gelsomino F; Aglietta M; Wong M; Limon Miron ML; Leonard G; García-Alfonso P; Hill AG; Cubillo Gracian A; Van Cutsem E; El-Rayes B; McCraith SM; He B; Lei M; Lonardi S
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38821718
[TBL] [Abstract] [Full Text] [Related]
16. Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway.
Park SJ; Kweon S; Moyo MK; Kim HR; Choi JU; Lee NK; Maharjan R; Cho YS; Park JW; Byun Y
Biomaterials; 2024 Oct; 310():122625. PubMed ID: 38820768
[TBL] [Abstract] [Full Text] [Related]
17. NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world evidence analysis.
Tang W; Li C; Huang D; Zhou S; Zheng H; Wang Q; Zhang X; Fu J
Cancer Biol Ther; 2024 Dec; 25(1):2358551. PubMed ID: 38813753
[TBL] [Abstract] [Full Text] [Related]
18. pd-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
[TBL] [Abstract] [Full Text] [Related]
19. Neoadjuvant immunotherapy in microsatellite instability-high (MSI-H) duodenal adenocarcinoma leads to pathological complete response and paves the way for new strategies.
Ziane Bouziane S; Mans L; Bucalau AM; Demetter P; Pezzullo M; Andre C; Loi P; Navez J; Marcelis L; Puleo F; Charette N; Closset J; Van Laethem JL
Eur J Cancer; 2024 Jul; 206():114128. PubMed ID: 38805957
[TBL] [Abstract] [Full Text] [Related]
20. ARHGAP4 promotes colon cancer metastasis through the TGF-β signaling pathway and may be associated with T cell exhaustion.
Jiang S; Tang Y; Wang X; Guo H; Chen L; Hu G; Cui Y; Liang S; Zuo J; Luo Z; Chen X; Wang X
Biochem Biophys Res Commun; 2024 Aug; 722():150172. PubMed ID: 38805788
[TBL] [Abstract] [Full Text] [Related]
[Next]
